tradingkey.logo

HeartSciences Inc

HSCS
查看詳細走勢圖
2.580USD
-0.060-2.27%
收盤 12/24, 13:00美東報價延遲15分鐘
7.92M總市值
虧損本益比TTM

HeartSciences Inc

2.580
-0.060-2.27%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.27%

5天

+16.74%

1月

+1.98%

6月

-32.64%

今年開始到現在

-32.46%

1年

-30.05%

查看詳細走勢圖

TradingKey HeartSciences Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

HeartSciences Inc當前公司基本面數據相對穩定,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名143/206位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價13.50。中期看,股價處於下降通道。近一個月,市場表現一般,基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間,可以做區間波段操作。

HeartSciences Inc評分

相關信息

行業排名
143 / 206
全市場排名
389 / 4562
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
13.500
目標均價
+363.92%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

HeartSciences Inc亮點

亮點風險
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
業績增長期
公司處於發展階段,最新年度總收入4.35K美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入4.35K美元
估值合理
公司最新PE估值-0.39,處於3年歷史合理位
機構加倉
最新機構持股108.58K股,環比增加31.39%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉18.56K股

HeartSciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

HeartSciences Inc簡介

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
公司代碼HSCS
公司HeartSciences Inc
CEOSimpson (Andrew)
網址https://heartsciences.com/

常見問題

HeartSciences Inc(HSCS)的當前股價是多少?

HeartSciences Inc(HSCS)的當前股價是 2.580。

HeartSciences Inc 的股票代碼是什麼?

HeartSciences Inc的股票代碼是HSCS。

HeartSciences Inc股票的52週最高點是多少?

HeartSciences Inc股票的52週最高點是6.470。

HeartSciences Inc股票的52週最低點是多少?

HeartSciences Inc股票的52週最低點是2.010。

HeartSciences Inc的市值是多少?

HeartSciences Inc的市值是7.92M。

HeartSciences Inc的淨利潤是多少?

HeartSciences Inc的淨利潤為-8.77M。

現在HeartSciences Inc(HSCS)的股票是買入、持有還是賣出?

根據分析師評級,HeartSciences Inc(HSCS)的總體評級為買入,目標價格為13.500。

HeartSciences Inc(HSCS)股票的每股收益(EPS TTM)是多少

HeartSciences Inc(HSCS)股票的每股收益(EPS TTM)是-6.567。
KeyAI